<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial treatment and prognosis of IDH-wildtype glioblastoma in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial treatment and prognosis of IDH-wildtype glioblastoma in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Initial treatment and prognosis of IDH-wildtype glioblastoma in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tracy Batchelor, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Y Wen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H13374802"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Glioblastoma is the most common malignant primary brain tumor in adults, with a median age of onset of approximately 55 to 60 years. As of the 2021 revision of the World Health Organization (WHO) Classification of Central Nervous System (CNS) Tumors, tumors previously called glioblastoma are now divided into two separate diagnoses based primarily on isocitrate dehydrogenase (IDH) mutation status  (<a class="graphic graphic_algorithm graphicRef134946" href="/z/d/graphic/134946.html" rel="external">algorithm 1</a>) [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Glioblastoma, IDH-wildtype, CNS WHO grade 4</p><p class="bulletIndent1"><span class="glyph">●</span>Astrocytoma, IDH-mutant, CNS WHO grade 4</p><p></p><p>For the purposes of this topic, glioblastoma refers to IDH-wildtype glioblastoma unless specifically stated otherwise. IDH-mutant grade 4 astrocytomas are discussed along with other IDH-mutant astrocytomas. (See  <a class="medical medical_review" href="/z/d/html/5198.html" rel="external">"Treatment and prognosis of IDH-mutant astrocytomas in adults"</a>.)</p><p>Most patients with glioblastoma are managed with a combined-modality approach, incorporating adjuvant postoperative radiation therapy and adjuvant chemotherapy following initial surgery. Even with maximal therapy, glioblastoma has a high rate of recurrence and poor overall survival, ranging from 1.5 to 2 years.</p><p>Selection and administration of initial systemic therapy, monitoring, and prognosis are reviewed here. Other topics that are covered separately include:</p><p class="bulletIndent1"><span class="glyph">●</span>(see  <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>(see  <a class="medical medical_review" href="/z/d/html/5180.html" rel="external">"Overview of the clinical features and diagnosis of brain tumors in adults"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>(see  <a class="medical medical_review" href="/z/d/html/5228.html" rel="external">"Clinical presentation, diagnosis, and initial surgical management of high-grade gliomas"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>(see  <a class="medical medical_review" href="/z/d/html/5225.html" rel="external">"Radiation therapy for high-grade gliomas"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>(see  <a class="medical medical_review" href="/z/d/html/15246.html" rel="external">"Management of glioblastoma in older adults"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>(see  <a class="medical medical_review" href="/z/d/html/5205.html" rel="external">"Management of recurrent high-grade gliomas"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>(see  <a class="medical medical_review" href="/z/d/html/5198.html" rel="external">"Treatment and prognosis of IDH-mutant astrocytomas in adults"</a>)</p><p></p><p class="headingAnchor" id="H1807808022"><span class="h1">SURGICAL RESECTION</span><span class="headingEndMark"> — </span>A histologic diagnosis is required for optimal treatment of patients with brain tumors. This can be accomplished either at the time of surgical resection or with a stereotactic biopsy. Biopsy alone is used in situations where the lesion is not amenable to resection, a meaningful amount of tumor tissue cannot be removed, or the patient's overall clinical condition will not permit surgery.</p><p>For patients with glioblastoma, maximal surgical resection consistent with preservation of neurologic function is preferred. Although gross total resection is preferred whenever possible, subtotal resection or biopsy alone may be required depending upon the location and extent of the tumor. (See  <a class="medical medical_review" href="/z/d/html/5228.html" rel="external">"Clinical presentation, diagnosis, and initial surgical management of high-grade gliomas"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">ADJUVANT RADIATION THERAPY</span><span class="headingEndMark"> — </span>Adjuvant radiation therapy is a standard component of therapy for glioblastoma and has been shown to improve local control and survival after resection. Treatment field, dose, and delivery methods of radiation therapy for glioblastoma are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5225.html" rel="external">"Radiation therapy for high-grade gliomas"</a>.)</p><p class="headingAnchor" id="H3060653872"><span class="h1">SELECTION OF SYSTEMIC THERAPY</span><span class="headingEndMark"> — </span>Selection of appropriate systemic therapy for patients with glioblastoma and other infiltrative gliomas depends on adequate molecular characterization  (<a class="graphic graphic_table graphicRef115919" href="/z/d/graphic/115919.html" rel="external">table 1</a>). For glioblastoma, tumor specimens should be tested for O6-methylguanine-DNA methyltransferase (<em>MGMT</em>) promoter methylation and for isocitrate dehydrogenase (IDH) type 1 or type 2 mutations (particularly in patients &lt;55 years of age). Methods of testing and the proportion of tumors with these alterations are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on 'Key molecular diagnostic tests'</a> and  <a class="medical medical_review" href="/z/d/html/5228.html" rel="external">"Clinical presentation, diagnosis, and initial surgical management of high-grade gliomas", section on 'Pathology'</a> and <a class="local">'MGMT methylation status'</a> below.)</p><p>While the presence of an <em>IDH1/2</em> mutation does not yet have treatment implications for upfront therapy in routine clinical practice, it does confer significantly improved prognosis and may impact clinical trial eligibility. In addition, most <em>IDH1/2</em>-mutant grade 4 astrocytomas also show methylation of the <em>MGMT</em> promoter, which is relevant to treatment selection as well as prognosis. Methylation of the <em>MGMT</em> promoter in glioblastoma leads to gene silencing and loss of expression of the MGMT DNA repair protein, which is predictive of benefit from alkylating agent chemotherapy and prognostic of improved survival. (See  <a class="medical medical_review" href="/z/d/html/5228.html" rel="external">"Clinical presentation, diagnosis, and initial surgical management of high-grade gliomas", section on 'Pathology'</a> and <a class="local">'MGMT methylation status'</a> below.)</p><p class="headingAnchor" id="H897170729"><span class="h2"><i>MGMT</i>-methylated tumors, age ≤70 years</span><span class="headingEndMark"> — </span>For patients with newly diagnosed <em>MGMT</em>-methylated glioblastoma who are 70 years of age or younger, we recommend use of concurrent <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> in combination with radiation therapy followed by monthly adjuvant temozolomide. A dual regimen of temozolomide and <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">lomustine</a> in combination with radiation therapy is an alternative option in younger, fit patients with <em>MGMT</em>-methylated tumors, although data supporting improved efficacy are inconclusive and toxicity may be higher.</p><p>The efficacy of concurrent and adjuvant treatment with <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> in adults with glioblastoma was first shown by a European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada (EORTC/NCIC) open-label trial in which 573 patients age 18 to 70 years were randomly assigned to receive involved-field radiation therapy alone or radiation plus concurrent daily temozolomide followed by up to six monthly cycles of adjuvant temozolomide [<a href="#rid2">2</a>]. With a median follow-up of over five years, the addition of temozolomide to radiation improved median overall survival compared with radiation alone (14.6 versus 12.1 months, hazard ratio [HR] 0.63, 95% CI 0.53-0.75) [<a href="#rid2">2</a>]. With long-term follow-up, survival continued to be superior in the temozolomide arm at two years (27 versus 11 percent) and five years (10 versus 2 percent) [<a href="#rid3">3</a>]. Grade 3 or 4 hematologic toxicity was more common in the temozolomide arm, primarily thrombocytopenia (12 percent) and lymphopenia (7 percent), but health-related quality of life was maintained [<a href="#rid2">2,4</a>]. Benefits from adjuvant temozolomide were observed in all patient subsets, including those over 60 years and those with other poor prognostic factors [<a href="#rid2">2,3</a>]. Similar results were seen in a second, smaller phase II trial in patients with glioblastoma [<a href="#rid5">5</a>].</p><p>In an analysis of a subset of 206 patients in the EORTC/NCIC trial for whom <em>MGMT</em> methylation status was determined retrospectively, methylation of the<em> MGMT</em> promoter was a major prognostic factor for improved survival and was predictive of benefit from chemotherapy [<a href="#rid6">6</a>]. For those with<em> MGMT</em> methylation (45 percent of cases), the addition of <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> was associated with a doubling of two-year overall survival compared with radiation alone (46 versus 23 percent; median overall survival 21.7 versus 15.3 months, HR 0.45, 95% CI 0.32-0.61) [<a href="#rid6">6</a>]. For those without<em> MGMT</em> methylation, there was a smaller difference in survival that was not statistically significant (two-year survival 14 versus &lt;2 percent; median overall survival 12.7 versus 11.8 months, HR 0.69, 95% CI 0.47-1.02).</p><p>Subsequent trials in patients with <em>MGMT</em>-methylated glioblastoma have attempted to improve upon the standard of radiation plus <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>. One such trial (CeTeG/NOA-09) screened &gt;650 patients to enroll 141 patients age 18 to 70 years with <em>MGMT</em>-methylated glioblastoma and randomly assign them to a combined lomustine/temozolomide regimen during and after radiation therapy (up to six 42-day cycles of <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">lomustine</a> 100 mg/m<sup>2</sup> on day 1 plus temozolomide 100 mg/m<sup>2</sup> on days 2 to 6) or standard therapy (daily temozolomide with radiation therapy followed by up to six cycles of adjuvant monthly temozolomide) [<a href="#rid7">7</a>]. Randomization was stratified by center. Twelve randomized patients (six in each arm) dropped out prior to receiving therapy, leaving 129 patients in a modified intent-to-treat (mITT) analysis. The sex distribution was statistically different between treatment groups, and multiple other baseline prognostic factors were numerically different between groups. In the mITT population, median overall survival was similar for lomustine/temozolomide versus standard temozolomide (37.9 versus 31.4 months, HR 0.90, 95% CI 0.58-1.41). An adjusted mITT analysis on these 129 patients using inverse probability weights found a nonsignificant trend towards improved survival in the lomustine/temozolomide arm (HR 0.74, 95% CI 0.47-1.17) and no difference in progression-free survival (HR 0.99, 95% CI 0.68-1.46). Prespecified analyses, which included matching by center and recursive partitioning analysis (RPA) class, excluded 32 randomized patients; in this matched analysis (n = 109), overall survival was improved in the combination arm (48.1 versus 31.4 months, HR 0.60, 95% CI 0.35-1.03) and progression-free survival was similar (16.7 months in both groups). Grade 3 or 4 hematologic toxicity was more common with combination therapy (36 versus 29 percent); nausea was also more common with combination therapy (30 versus 19 percent). The rate of completion of all six cycles of chemotherapy was 39 percent for lomustine/temozolomide and 60 percent for standard temozolomide.</p><p>These results are provocative and support the conclusion that <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">lomustine</a>/<a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> combination therapy might improve survival compared with standard temozolomide in selected younger, fit patients with <em>MGMT</em>-methylated glioblastoma. However, confidence in the superior efficacy of combination therapy is reduced by limitations of the trial, including small size and exclusion of a significant number of randomized patients in the prespecified analyses. In addition, combination therapy is associated with higher risks of nausea and hematologic toxicity, which may lead some patients and clinicians to reasonably choose standard temozolomide pending further studies.</p><p class="headingAnchor" id="H1827162442"><span class="h2"><i>MGMT</i>-unmethylated tumors, age ≤70 years</span><span class="headingEndMark"> — </span>Patients with <em>MGMT</em>-unmethylated tumors have a poor prognosis and response to standard therapies and are encouraged to participate in clinical trials. Outside of a clinical trial, we suggest use of <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> along with radiation in most patients with <em>MGMT</em>-unmethylated glioblastoma, based on results of the EORTC/NCIC trial, in which <em>MGMT </em>status was not known prospectively [<a href="#rid2">2,3</a>].</p><p>Patients with <em>MGMT</em>-unmethylated tumors have worse overall survival and derive less benefit from <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> compared with patients with <em>MGMT</em>-methylated tumors, however. As discussed above, an analysis of 206 patients in the EORTC/NCIC trial for whom <em>MGMT</em> status was determined retrospectively found that among patients with <em>MGMT</em>-unmethylated tumors (n = 114), the addition of temozolomide to radiation therapy was associated with a small difference in survival that was not statistically significant (two-year survival 15 versus 2 percent; median overall survival 12.7 versus 11.8 months, HR 0.69, 95% CI 0.47-1.02) [<a href="#rid6">6</a>].</p><p>Alternatives to <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> are being actively investigated in patients with <em>MGMT</em>-unmethylated tumors. As an example, a randomized, unblinded phase II study of 182 patients with newly diagnosed <em>MGMT</em>-unmethylated glioblastoma compared <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> during radiation followed by bevacizumab plus <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> with radiation plus concurrent and adjuvant temozolomide [<a href="#rid8">8</a>]. Similar to the trials reviewed below in unselected glioblastoma, the bevacizumab regimen was associated with improved six-month progression-free survival (79 versus 43 percent) but no difference in median overall survival (16.6 versus 17.5 months) or quality-of-life outcomes. Two-thirds of the patients in the temozolomide group received bevacizumab at progression. A separate trial comparing radiation plus <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> with radiation plus concurrent and adjuvant temozolomide found that survival was worse in the nivolumab arm (median overall survival 13.4 versus 14.9 months, HR 1.31, 95% CI 1.09-1.58) [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H2084870925"><span class="h2"><i>MGMT</i> status unknown</span><span class="headingEndMark"> — </span>Assays to determine <em>MGMT</em> methylation status are not successful in a sizable minority of patients due to insufficient tissue, particularly those who undergo stereotactic biopsy. When <em>MGMT</em> status is not known at the time of postoperative decision-making and the patient is otherwise a candidate for standard therapy (ie, age ≤70 years, good functional status), we recommend use of <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> in combination with radiation therapy. The rationale is based on the clinically meaningful improvement in survival expected from temozolomide for the 30 to 40 percent of patients predicted to have an <em>MGMT</em>-methylated tumor, the lack of better alternatives for <em>MGMT</em>-unmethylated tumors, and the relative safety and tolerability of temozolomide. (See <a class="local">'MGMT-methylated tumors, age ≤70 years'</a> above.)</p><p class="headingAnchor" id="H3533437874"><span class="h2">Older adults and those with poor functional status</span><span class="headingEndMark"> — </span>Combined-modality therapy is the standard of care for younger patients with glioblastoma, but with advancing age or low functional status the benefits become more closely balanced with risks of toxicity and side effects. An approach to initial treatment decisions in adults &gt;70 years of age and those with low functional status  (<a class="graphic graphic_algorithm graphicRef93333" href="/z/d/graphic/93333.html" rel="external">algorithm 2</a>) is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15246.html" rel="external">"Management of glioblastoma in older adults"</a>.)</p><p class="headingAnchor" id="H1623273310"><span class="h2">Limited role of bevacizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">Bevacizumab</a>, a monoclonal antibody that binds to vascular endothelial growth factor (VEGF), is not recommended for routine use in patients with newly diagnosed glioblastoma [<a href="#rid10">10</a>]. Although bevacizumab has potent antiedema effects, which can improve clinical function and reduce glucocorticoid requirements in selected patients, it does not improve overall survival when used as part of initial therapy and increases the risk of toxicity [<a href="#rid11">11</a>].</p><p>We do consider early <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> as a supportive medication in selected patients with bulky, nonresectable tumors in an attempt to control refractory edema and mass effect that may arise during or shortly after completion of radiation therapy. (See  <a class="medical medical_review" href="/z/d/html/5205.html" rel="external">"Management of recurrent high-grade gliomas", section on 'Bevacizumab'</a>.)</p><p>While the use of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> in the up-front setting appeared promising in phase II studies [<a href="#rid12">12-14</a>], this benefit was not confirmed in two large randomized trials [<a href="#rid15">15,16</a>]. In the AVAglio study, 921 patients were randomly assigned to receive bevacizumab or placebo in conjunction with radiation and <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> [<a href="#rid15">15</a>]. After completion of radiation, patients were treated with six cycles of monthly temozolomide plus bevacizumab or placebo every two weeks, followed by maintenance bevacizumab or placebo every three weeks until progression. The following results were observed:</p><p class="bulletIndent1"><span class="glyph">●</span>Median progression-free survival was improved in patients treated with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> compared with placebo (10.6 versus 6.2 months, HR 0.64, 95% CI 0.55-0.74). Similarly, baseline health-related quality of life and performance status were maintained longer in the bevacizumab group [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Median overall survival was not significantly different (HR 0.88, 95% CI 0.76-1.02).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was an increase in the rate of serious adverse events in patients treated with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> compared with placebo (67 versus 51 percent).</p><p></p><p>In the Radiation Therapy Oncology Group (RTOG) 0825 study, 637 patients were randomly assigned to receive <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> or placebo starting at week 4 of standard chemoradiation with <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>, followed by 6 to 12 cycles of maintenance temozolomide plus bevacizumab or placebo [<a href="#rid16">16</a>]. The following results were observed:</p><p class="bulletIndent1"><span class="glyph">●</span>Median progression-free survival was improved in patients treated with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> compared with placebo (10.7 versus 7.3 months, p = 0.007), but the result did not meet the predefined significance threshold of p &lt;0.004.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Median overall survival did not differ in patients treated with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> compared with placebo (15.7 versus 16.1 months, p = 0.21).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>MGMT</em> promoter methylation was associated with improved progression-free survival (14 versus 8 months) and overall survival (23 versus 14 months), regardless of study treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was an increased rate of serious adverse events in patients treated with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, primarily neutropenia, hypertension, and thromboembolism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> group experienced an increased symptom burden, worse quality of life, and more frequent decline in neurocognitive function compared with the placebo group [<a href="#rid18">18</a>].</p><p></p><p class="headingAnchor" id="H3860071533"><span class="h2">Investigational therapies and clinical trials</span><span class="headingEndMark"> — </span>A variety of therapies are being explored in clinical trials for patients with newly diagnosed glioblastoma, typically in combination with radiation and <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> chemotherapy. Most studies are testing either molecularly targeted agents or biologic approaches such as immunotherapy, vaccine-based therapies, or local gene therapy. A searchable database of clinical trials is available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=5207" target="_blank">United States National Library of Medicine</a>.</p><p>Further information on tumor genotyping and emerging therapies for glioblastoma can be found separately. (See  <a class="medical medical_review" href="/z/d/html/5228.html" rel="external">"Clinical presentation, diagnosis, and initial surgical management of high-grade gliomas", section on 'Role of tumor genome sequencing'</a> and  <a class="medical medical_review" href="/z/d/html/5205.html" rel="external">"Management of recurrent high-grade gliomas", section on 'Genotype-directed therapies'</a>.)</p><p class="headingAnchor" id="H1628816380"><span class="h1">ADMINISTRATION OF SYSTEMIC THERAPY</span></p><p class="headingAnchor" id="H5"><span class="h2">Temozolomide</span></p><p class="headingAnchor" id="H2030822282"><span class="h3">Dose and schedule</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">Temozolomide</a> is an oral alkylating agent that is dosed based on body surface area (BSA). During radiation, temozolomide is given daily (seven days per week) at a dose of 75 mg/m<sup>2</sup>. Temozolomide is taken on an empty stomach, at least two hours after the last meal.</p><p>Some clinicians advise patients to time weekday doses of <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> one hour before radiation therapy, in theory to maximize synergy with radiation. Other clinicians have patients take their dose at the same time each day, either first thing in the morning before eating breakfast or at bedtime, two or more hours after dinner.</p><p>During the concomitant phase, weekly complete blood counts (CBCs) are required for monitoring. <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">Temozolomide</a> should be held if platelets fall below 100,000/microL or absolute neutrophil count (ANC) falls below 1500/microL, as counts can fall precipitously  (<a class="graphic graphic_table graphicRef128463" href="/z/d/graphic/128463.html" rel="external">table 2</a>). More frequent monitoring may be necessary thereafter until nadirs are determined.</p><p>The first postradiation cycle of <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> typically begins four weeks after completion of radiation therapy and is given at a dose of 150 mg/m<sup>2</sup> daily for 5 days out of a 28-day cycle  (<a class="graphic graphic_figure graphicRef128466" href="/z/d/graphic/128466.html" rel="external">figure 1</a> and <a class="graphic graphic_table graphicRef128464 graphicRef128465" href="/z/d/graphic/128464.html" rel="external">table 3A-B</a>). Subsequent cycles (2 through 6) are dosed at 200 mg/m<sup>2</sup> if blood counts are acceptable. A CBC should be obtained on days 22 and 29 of each cycle, along with monthly basic metabolic panel and liver function tests, to monitor for toxicity and help guide dose adjustments, if necessary. Clinicians should reference temozolomide product labeling for dosing modifications of hematologic toxicity. (See <a class="local">'Side effects and monitoring'</a> below.)</p><p>Other schedules of <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> have not been shown to be more effective than the standard postradiation schedule of 5 days every 28 days in the adjuvant setting [<a href="#rid19">19-21</a>].</p><p class="headingAnchor" id="H3647526603"><span class="h3">Antiemetics</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">Temozolomide</a> is moderately emetogenic, and premedication with an oral serotonin 5-hydroxytryptamine (5-HT3) antagonist such as <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> 8 mg orally should be given 30 minutes before each dose. Both temozolomide and ondansetron are constipating, and patients should receive instructions for a maintenance bowel regimen. Some patients find that 4 mg of ondansetron is less constipating than 8 mg yet still adequate for prevention of nausea.</p><p class="headingAnchor" id="H4227936625"><span class="h3">Pneumocystis prophylaxis</span><span class="headingEndMark"> — </span>Antimicrobial prophylaxis for pneumocystis pneumonia is recommended in the <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> labeling information for all patients during the concomitant radiation phase of treatment. This guidance is based on the risk of selective lymphopenia and impaired T cell-mediated immunity with daily temozolomide as well as the occurrence of two cases of pneumocystis pneumonia in an initial phase II trial in patients with newly diagnosed glioblastoma [<a href="#rid22">22</a>].</p><p>However, clinical experience in the years since the approval of <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> for glioblastoma suggests that pneumocystis pneumonia is uncommon and usually occurs in patients with additional risk factors for opportunistic infection, such as use of glucocorticoids or lymphopenia. In a population-based retrospective cohort study that included more than 5000 Canadian patients with gliomas treated with temozolomide chemoradiotherapy, 38 patients (0.74 percent) were diagnosed with pneumocystis pneumonia within one year of treatment, at an average of approximately three months from the start of radiation [<a href="#rid23">23</a>]. The number of case fatalities was low (&lt;6 patients). A separate study on a subset of the same cohort for which data on pneumocystis prophylaxis use (mostly <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>) were available found that the absolute risk reduction associated with prophylaxis was low (estimated number needed to treat to prevent one infection: 288), while the risk of grade 3/4 neutropenia was elevated (number needed to harm: 34) [<a href="#rid24">24</a>]. Overall survival and hospitalization rates were similar between groups.</p><p>Based on these data, and considering other risks of <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (eg, thrombocytopenia, hypersensitivity, acute kidney injury), we have adopted a more selective approach to prophylaxis, prescribing it only in patients with additional risk factors for opportunistic infection (eg, glucocorticoid use, lymphopenia). This selective strategy has not been studied prospectively, however, and it remains reasonable to abide by the labeling information in all patients [<a href="#rid25">25</a>]. When used, prophylaxis is typically continued until lymphocytes have recovered to &gt;800/microL  (<a class="graphic graphic_table graphicRef79988" href="/z/d/graphic/79988.html" rel="external">table 4</a>) [<a href="#rid26">26,27</a>]. (See  <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Regimens'</a>.)</p><p class="headingAnchor" id="H71424865"><span class="h3">Side effects and monitoring</span></p><p class="headingAnchor" id="H3554490491"><span class="h4">Hematologic toxicities</span><span class="headingEndMark"> — </span>Patients receiving <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> chemotherapy are at risk for hematologic toxicity and should be monitored with weekly CBCs during radiation therapy  (<a class="graphic graphic_table graphicRef128463" href="/z/d/graphic/128463.html" rel="external">table 2</a>). The incidence of hematologic toxicity due to temozolomide is approximately two to three times higher in females than in males for reasons that are not yet clear [<a href="#rid28">28-31</a>].</p><p>During monthly cycles of adjuvant <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>, a CBC should be obtained on days 22 and 29 of each cycle to monitor for toxicity and help guide dose adjustments, if necessary  (<a class="graphic graphic_figure graphicRef128466" href="/z/d/graphic/128466.html" rel="external">figure 1</a> and <a class="graphic graphic_table graphicRef128464 graphicRef128465" href="/z/d/graphic/128464.html" rel="external">table 3A-B</a>). Subsequent cycles should not be given until platelets have recovered to &gt;100,000/microL and the ANC is &gt;1500/microL.</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate to severe thrombocytopenia is the most common hematologic adverse effect, occurring in approximately 10 to 20 percent of patients [<a href="#rid28">28</a>]. During the concurrent phase of therapy, daily <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> should be held if the platelet count falls below 100,000/microL.</p><p></p><p class="bulletIndent1">Radiation therapy is not known to increase bleeding risk and can be continued safely during periods of mild to moderate thrombocytopenia. In patients with severe thrombocytopenia (eg, counts less than 10,000 to 20,000/microL), some practitioners elect to hold radiation until hematologic stability has been achieved.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate to severe lymphopenia and neutropenia occur in at least 15 percent of patients, and up to 75 percent of patients have CD4+ T cell counts less than 300 cells per mm<sup>3</sup> at the completion of six weeks of daily <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> with concurrent radiotherapy [<a href="#rid29">29</a>]. In one retrospective study that included 183 patients receiving concurrent radiation and daily temozolomide, the rate of acute severe lymphopenia (ASL; defined as total lymphocyte count &lt;500/microL) was 29 percent within three months of starting radiation [<a href="#rid32">32</a>]. Risk factors for ASL include female sex, lower baseline lymphocyte count, and large radiation volume [<a href="#rid30">30,32</a>].</p><p></p><p>With appropriate dose delays and dose reductions, most patients are able to complete the intended number of cycles of adjuvant <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>. Secondary prophylaxis with growth factor support is not routinely used or required. Patients who develop severe grade 3/4 thrombocytopenia during concurrent radiation therapy may be an exception, and some of these patients have prolonged thrombocytopenia and platelet transfusion requirements.</p><p>Use of a thrombopoietin receptor agonist is a potential strategy to improve future exposure to <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> after dose-limiting thrombocytopenia, although further data are needed. A small feasibility study found that weekly subcutaneous <a class="drug drug_general" data-topicid="9493" href="/z/d/drug information/9493.html" rel="external">romiplostim</a> was safe as secondary prophylaxis in patients with temozolomide-induced thrombocytopenia [<a href="#rid33">33</a>]. Among 16 patients who developed grade 3/4 thrombocytopenia during radiation and received continuous weekly romiplostim beginning one week after completion of radiation therapy, nine patients were able to complete six cycles of adjuvant temozolomide, three patients never started adjuvant temozolomide due to failure of romiplostim, and the remaining patients came off study for progression or unrelated adverse events. Even with romiplostim, the majority of patients had recurrent grade 3/4 thrombocytopenia and required dose reductions and delays. There were no major bleeding events. A randomized trial is planned to assess whether romiplostim improves patient-important outcomes including transfusion requirements, bleeding complications, and survival. (See  <a class="medical medical_review" href="/z/d/html/6671.html" rel="external">"Clinical applications of thrombopoietic growth factors"</a>.)</p><p>Rare cases of temozolomide-associated aplastic anemia, myelodysplasia, plasmablastic lymphoma, and treatment-related acute myeloid leukemia (t-AML) have been described [<a href="#rid34">34-37</a>]. Aplastic anemia typically manifests as early and profound myelosuppression during the course of daily <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> with concurrent radiation [<a href="#rid36">36-44</a>]. The estimated incidence is &lt;1 percent among patients receiving temozolomide for central nervous system (CNS) malignancies [<a href="#rid37">37</a>]. Approximately two-thirds of patients achieve hematologic recovery; among those who do not, many succumb to complications of pancytopenia.</p><p>Cases of secondary t-AML and other hematologic malignancies in association with <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> exposure have mostly been in patients with previous exposure to other alkylating agents [<a href="#rid45">45-52</a>]. In three cases with no other leukemogenic drug exposures, the total duration of temozolomide exposure ranged from 22 to 28 months and the latency ranged from 3 to 36 months [<a href="#rid34">34</a>]. Deletion of chromosomes 5 and 7 was the most common cytogenic abnormality. (See  <a class="medical medical_review" href="/z/d/html/4506.html" rel="external">"Therapy-related myeloid neoplasms: Epidemiology, causes, evaluation, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2454355940"><span class="h4">Nonhematologic toxicities</span><span class="headingEndMark"> — </span>The most common nonhematologic side effects of <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> are nausea, anorexia, and fatigue. Fatal and severe hepatotoxicity has been reported in patients receiving temozolomide [<a href="#rid34">34,53-55</a>]. The manufacturer's product labeling recommends that liver biochemical tests be performed at baseline, midway through the first cycle, prior to each subsequent cycle, and approximately two to four weeks after the last dose of temozolomide [<a href="#rid56">56</a>]. Patients with mild to moderate hepatic dysfunction have similar pharmacokinetics compared with those with normal function, although patients with severe hepatic dysfunction have not been studied [<a href="#rid57">57</a>].</p><p>In addition to severe hepatotoxicity, other rare but life-threatening idiosyncratic reactions reported in association with <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> include hypersensitivity pneumonitis, allergic skin reactions, and opportunistic infections [<a href="#rid34">34</a>].</p><p>Fetal harm and adverse developmental outcomes associated with <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> exposure have been reported in both pregnant patients and pregnant partners of male patients, as well as in animal studies [<a href="#rid58">58</a>]. Patients of childbearing potential should be counseled on effective contraception as well as options for fertility preservation before beginning therapy, if possible. (See  <a class="medical medical_review" href="/z/d/html/5221.html" rel="external">"Treatment and prognosis of IDH-mutant, 1p/19q-codeleted oligodendrogliomas in adults", section on 'Reproductive health'</a>.)</p><p class="headingAnchor" id="H5986212"><span class="h3">Treatment duration</span><span class="headingEndMark"> — </span>Our practice is generally to treat with up to six cycles of postradiation <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>, based on the design of the original study that led to the acceptance of temozolomide as the standard of care [<a href="#rid2">2</a>]. Patients with stable disease after six cycles enter surveillance, with magnetic resonance imaging (MRI) every two to three months. Continuing temozolomide longer than six cycles in stable patients has not been shown to prolong survival but does expose patients to ongoing side effects and risks of chemotherapy.</p><p>Supporting evidence for this approach includes results of a phase II randomized trial, in which 159 patients with glioblastoma who had not progressed after six cycles of adjuvant <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> were randomly assigned to stop temozolomide (control) or continue temozolomide for up to 12 total cycles [<a href="#rid59">59</a>]. With a median follow-up of 33 months, progression-free survival was similar between groups, and overall survival was nonsignificantly worse in the extended temozolomide group (hazard ratio [HR] 1.3, 95% CI 0.90-1.88). The incidence of lymphopenia, thrombocytopenia, and nausea was higher in the extended temozolomide group. In secondary analyses, neither <em>MGMT</em> methylation status nor measurable disease were predictive of benefit from additional temozolomide cycles, with the limitation that the study had limited power to exclude clinically important differences.</p><p>Observational studies have come to similar conclusions [<a href="#rid60">60,61</a>]. In a retrospective study of 624 patients enrolled in one of four randomized trials who were free of progression after six cycles of adjuvant <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>, receipt of more than six cycles of temozolomide was associated with improved progression-free survival, especially in patients with <em>MGMT</em>-methylated tumors (HR 0.65, 95% CI 0.50-0.85), but no difference in overall survival (HR 0.92, 95% CI 0.71-1.19), even in the <em>MGMT</em>-methylated subgroup (HR 0.89, 95% CI 0.63-1.26) [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H2925977483"><span class="h2">Temozolomide and lomustine</span><span class="headingEndMark"> — </span>In the CeTeG/NOA-09 trial, combined <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> and <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">lomustine</a> was administered in six-week cycles starting during the first week of radiation therapy [<a href="#rid7">7</a>]. The first cycle was dosed as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">Lomustine</a> (CCNU) 100 mg/m<sup>2</sup> orally on day 1</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">Temozolomide</a> 100 mg/m<sup>2</sup> on days 2 to 6</p><p></p><p>Weekly CBCs should be performed during radiation therapy to monitor for hematologic toxicity, similar to the procedure in patients treated with daily <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>. In subsequent cycles, CBCs should be performed weekly starting at day 21. Basic metabolic panel and liver biochemical tests should be performed at the beginning and halfway through each cycle.</p><p>The risk of grade ≥3 hematologic toxicity in the CeTeG/NOA-09 trial was nonsignificantly higher with <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> plus <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">lomustine</a> compared with temozolomide alone (36 versus 29 percent) [<a href="#rid62">62</a>]. Toxicity mostly occurred during concurrent chemoradiotherapy; in patients who went on to receive one or more adjuvant cycles of chemotherapy, the risk of repeat hematologic toxicity was 42 percent. Risk factors for hematologic toxicity were female sex (odds ratio 2.5) and older age.</p><p>In the trial protocol, dosing of subsequent cycles was determined by the timing and depth of white blood cell (WBC) and platelet nadirs in relation to day 25. If a grade ≥3 nadir (WBC &lt;1500/microL or platelets &lt;50,000/microL) occurred <strong>after</strong> day 25, the next cycle of <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">lomustine</a> was dosed at 75 percent of the initial dose. One further dose reduction was permitted (to 50 percent of cycle 1 dose) for a grade ≥3 nadir in a subsequent cycle. Lomustine was permanently discontinued for a grade ≥3 toxicity after two dose reductions.</p><p><a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">Temozolomide</a> was adjusted according to nadirs during the first 25 days of the preceding cycle as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>WBC &lt;1000/microL or platelets &lt;25,000/microL – decrease to 50 mg/m<sup>2</sup> (daily on days 2 to 6) on next cycle. Discontinue permanently if WBC &lt;1500/microL or platelets &lt;50,000/microL at the lowest dose level of 50 mg/m<sup>2</sup>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>WBC 1000 to 1500/microL or platelets 25,000 to 50,000/microL – decrease to 75 mg/m<sup>2</sup> (daily on days 2 to 6) on next cycle.</p><p></p><p>Dose escalation of <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> to 120 mg/m<sup>2</sup> was permitted if none of the above nadirs occurred during the first 25 days of the first cycle and counts had recovered by the end of radiation (WBC &gt;2500/microL and platelets &gt;100,000/microL). Two further dose increases were permitted in subsequent cycles meeting these criteria, to 150 mg/m<sup>2</sup> and 200 mg/m<sup>2</sup>, respectively.</p><p><a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">Temozolomide</a> side effects are reviewed above (see <a class="local">'Side effects and monitoring'</a> above). <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">Lomustine</a> is a nitrosourea alkylating agent with overlapping hematologic toxicities and risk of severe myelosuppression. Like temozolomide, it is moderately emetogenic and should be given with adequate antinausea premedication. Other potential nonhematologic side effects include stomatitis, alopecia, progressive azotemia and nephrotoxicity, and hepatotoxicity. Pulmonary infiltrates and/or fibrosis can occur, usually at cumulative doses &gt;1000 mg/m<sup>2</sup>, and serial monitoring of pulmonary function tests is advised. (See  <a class="medical medical_review" href="/z/d/html/4354.html" rel="external">"Nitrosourea-induced pulmonary injury"</a>.)</p><p class="headingAnchor" id="H1275825974"><span class="h1">ALTERNATING ELECTRIC FIELDS</span><span class="headingEndMark"> — </span>A portable medical device applied to the scalp that generates TTFields first became available in 2011 for treatment of recurrent glioblastoma [<a href="#rid63">63</a>], and results of a subsequent open-label randomized trial suggest that the device improves both progression-free and overall survival when used along with monthly <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> in patients with newly diagnosed glioblastoma in the postradiation setting [<a href="#rid64">64,65</a>]. Use of the device is encouraged in interested patients, although the requirement to carry a device and maintain a shaved scalp for the duration of treatment presents a potential burden that is not acceptable to all patients.</p><p>Data supporting the role of TTFields in the up-front setting consist of an unblinded, multicenter international trial in which 695 patients with newly diagnosed glioblastoma were randomly assigned in a 2:1 fashion to monthly <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> plus TTFields or monthly temozolomide alone upon completion of standard radiation and concurrent daily temozolomide [<a href="#rid64">64,65</a>]. Eligible patients must have completed concurrent radiation and daily temozolomide without progression and were enrolled within seven weeks of completing radiation. The primary endpoint was progression-free survival. The trial was stopped early for benefit, at the time of a planned interim analysis of the first 315 patients with ≥18 months of follow-up; at this time trial enrollment had already reached the intended 695 patients [<a href="#rid64">64</a>].</p><p>Baseline patient characteristics were similar between the device arm (n = 466) and the control arm (n = 229) [<a href="#rid65">65</a>]. The median age was 56 years, the median Karnofsky Performance Status (KPS) was 90, and 54 percent of patients underwent gross total resection. <em>MGMT</em> promoter methylation status was available in 82 percent of patients and was methylated in 41 percent. MRI was reviewed centrally by two blinded radiologists according to Macdonald criteria. The median time from diagnosis to randomization was 3.8 months in both groups.</p><p>After a median follow-up of 40 months in surviving patients, those assigned to the TTFields device had improved progression-free survival compared with those assigned to <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> alone (6.7 versus 4.0 months, HR 0.63, 95% CI 0.52-0.76). Overall survival from the time of randomization was also improved (20.9 versus 16.0 months, HR 0.63, 95% CI 0.53-0.76). The most common device-related adverse effect was skin irritation (54 percent all grades, 2 percent severe), and the rate of systemic adverse effects did not differ between groups [<a href="#rid65">65</a>]. Secondary analysis of quality-of-life outcomes found no difference between the groups at 9 and 12 months [<a href="#rid66">66,67</a>].</p><p>A limitation of the trial was the lack of a sham device in the control arm, raising the possibility that differences in supportive care or health-promoting behaviors could have contributed to improved outcomes in the device arm. However, such an effect seems unlikely to fully explain the five-month difference in overall survival observed in the trial.</p><p>Experimentally, the biologic activity of the therapy is reported to derive from an antimitotic effect imposed by the alternating electric fields, which exert forces on charged tubulin subunits and thereby interfere with formation of the mitotic spindle [<a href="#rid68">68,69</a>].</p><p>Clinicians must be trained and certified to prescribe the device. The device is applied to a shaved scalp, with four transducer arrays connected to a portable battery or power supply-operated device. The device is intended to be worn continuously or at least 18 hours per day, and a shaved scalp must be maintained for the duration of therapy. Depending upon the functional status of the patient and the level of caregiver support, wearing and maintaining the device may represent a significant burden.</p><p class="headingAnchor" id="H2391765176"><span class="h1">FOLLOW-UP AND MONITORING</span></p><p class="headingAnchor" id="H1737436588"><span class="h2">Assessment of response and progression</span><span class="headingEndMark"> — </span>Patient management decisions require an assessment of both initial response to treatment and subsequent evidence of progressive disease. Brain MRI with contrast is typically obtained within one month after completion of radiation therapy and then every two months during adjuvant <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> to assess disease status.</p><p class="headingAnchor" id="H653878603"><span class="h2">Early progression versus pseudoprogression</span><span class="headingEndMark"> — </span>Pseudoprogression is a subacute treatment-related effect with MRI features mimicking tumor progression, usually occurring within three months of completion of chemoradiation in patients with glioblastoma  (<a class="graphic graphic_diagnosticimage graphicRef117429" href="/z/d/graphic/117429.html" rel="external">image 1</a>). Distinguishing treatment-induced imaging changes from progressive disease has important implications to avoid premature and inappropriate discontinuation of a treatment regimen. Pseudoprogression is more common in patients with <em>MGMT</em>-methylated glioblastoma. Diagnosis and management of pseudoprogression are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5205.html" rel="external">"Management of recurrent high-grade gliomas", section on 'Early progression versus pseudoprogression'</a>.)</p><p class="headingAnchor" id="H972495063"><span class="h2">Surveillance after treatment</span><span class="headingEndMark"> — </span>There are no formal clinical trials that define the optimal frequency for follow-up after treatment. Guidelines from the National Comprehensive Cancer Network (NCCN) recommend that a repeat MRI should be obtained in patients with glioblastoma approximately four weeks after completion of radiation therapy, then every two to four months for two to three years, and less frequently thereafter [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H2840800021"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The most important prognostic factors affecting outcome in patients with glioblastoma are age, Karnofsky Performance Status (KPS)  (<a class="graphic graphic_table graphicRef58785" href="/z/d/graphic/58785.html" rel="external">table 5</a>), <em>MGMT</em> status, and several additional molecular genetic alterations. As discussed above, the extent of initial surgical resection also appears to influence prognosis. (See  <a class="medical medical_review" href="/z/d/html/5228.html" rel="external">"Clinical presentation, diagnosis, and initial surgical management of high-grade gliomas", section on 'Extent of resection'</a>.)</p><p class="headingAnchor" id="H2586101251"><span class="h2">Population-based estimates</span><span class="headingEndMark"> — </span>The median overall survival of patients with glioblastoma in population-based studies is approximately 10 to 12 months [<a href="#rid71">71-73</a>]. For glioblastoma diagnosed between 2002 through 2010 in the United States and Taiwan, for example, one-year survival rates ranged from 38 to 50 percent and five-year survival ranged from 5 to 10 percent [<a href="#rid74">74</a>]. In a separate population-based study that examined changes in glioblastoma survival over a 20-year period, median overall survival for glioblastoma improved from 4.9 months in the period of 1980 through 1994 to 11.5 months in the period of 2005 through 2009 [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H176548016"><span class="h2">Patient-level prognostic tools</span><span class="headingEndMark"> — </span>A nomogram derived from a clinical trial population and validated on a separate trial cohort is available <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fnpatilshinyappcalculator.shinyapps.io%2FSexDifferencesInGBM%2F&amp;token=SxOBrOxNwEDzMVvWTMoIYgOqC%2FLlSCDT01Pw3kXuCimFsGKaIgG0DOaISUZd4b7IwD2TEnVbLlOA7A3Ah2zTxOYe7Sfs0%2Bl5NveNxovPl24%3D&amp;TOPIC_ID=5207" target="_blank">online</a> [<a href="#rid76">76</a>]. Nearly all patients included in the derivation and validation cohorts underwent at least subtotal resection and received standard radiation with concurrent <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> followed by monthly temozolomide; information on IDH mutation status was not available, but the majority can be assumed to have had IDH-wildtype tumors. The nomogram estimates are therefore likely most applicable to patients with IDH-wildtype glioblastoma. It has been validated in at least one cohort of nonclinical trial participants [<a href="#rid77">77</a>].</p><p>The nomogram incorporates patient age at diagnosis, sex, KPS, extent of resection, and <em>MGMT</em> status to estimate 6-, 12-, and 24-month survival probability [<a href="#rid76">76</a>]. As an example, the nomogram estimates that a 50-year-old male with a KPS of 90 who undergoes gross total resection of an <em>MGMT-</em>methylated tumor has 12- and 24-month survival probabilities of 80 and 52 percent, respectively. Survival probabilities for the same patient with an <em>MGMT-</em>unmethylated tumor are 27 and 10 percent, respectively.</p><p>A previously validated prognostic tool is the recursive partitioning analysis (RPA) classification of glioblastoma, which was developed in the pre-temozolomide era and validated on patients who received primarily radiation alone [<a href="#rid78">78</a>]. The classification estimates median survival in three subgroups:</p><p class="bulletIndent1"><span class="glyph">●</span>RPA class III (age &lt;50, KPS ≥90) – 17.1 months (12-month survival 70 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RPA class IV (age &lt;50, KPS &lt;90; or age ≥50, KPS ≥70, resection, and working) – 11.2 months (12-month survival 46 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RPA class V (all others) – 7.5 months (12-month survival 28 percent)</p><p></p><p>A similar analysis in older adults age ≥70 years identified four prognostic subgroups based on age, extent of surgery (biopsy versus resection), and KPS; median survival ranged from 2.3 months in subgroup IV (biopsy only, KPS &lt;70) to 9.3 months in subgroup I (surgical resection, age &lt;75.5) [<a href="#rid79">79</a>]. (See  <a class="medical medical_review" href="/z/d/html/15246.html" rel="external">"Management of glioblastoma in older adults", section on 'Prognostic factors'</a>.)</p><p class="headingAnchor" id="H1781604552"><span class="h2"><i>MGMT </i>methylation status</span><span class="headingEndMark"> — </span>MGMT is an enzyme that is responsible for DNA repair following alkylating-agent chemotherapy. In the course of tumor development, the <em>MGMT</em> gene may be silenced by methylation of its promoter, thereby preventing repair of DNA damage and increasing the potential effectiveness of alkylating agent chemotherapy.</p><p>Multiple clinical studies have confirmed that <em>MGMT</em> promoter methylation is prognostic of improved survival, independent of established clinical factors. In a meta-analysis of 11 studies examining the prognostic value of <em>MGMT</em> promoter status, a methylated <em>MGMT</em> promoter was associated with an improvement in both progression-free survival (hazard ratio [HR] 0.56, 95% CI 0.32-0.80) and overall survival (HR 0.50, 95% CI 0.35-0.66) [<a href="#rid80">80</a>].</p><p><em>MGMT</em> promoter methylation may also be predictive of chemotherapy responsiveness in patients with glioblastoma, although this has not been confirmed in a prospective manner [<a href="#rid6">6,81</a>]. In a large randomized trial comparing radiation alone with radiation plus concomitant and adjuvant <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>, the two-year overall survival for patients treated with combined radiation and chemotherapy was 49 percent for those with <em>MGMT</em>-methylated tumors and 15 percent for those with unmethylated tumors; moreover, those with a methylated <em>MGMT</em> promoter derived a greater degree of benefit from the addition of temozolomide to radiation than those with an unmethylated promoter. (See <a class="local">'Temozolomide'</a> above.)</p><p>This prognostic and predictive role of <em>MGMT</em> promoter methylation has also been observed in studies of older adults with glioblastoma and can be used to guide treatment [<a href="#rid82">82-84</a>]. (See  <a class="medical medical_review" href="/z/d/html/15246.html" rel="external">"Management of glioblastoma in older adults", section on 'Selection of therapy'</a>.)</p><p>The presence of methylation of the <em>MGMT</em> promoter may also influence the patterns of clinical relapse. This was illustrated by a study of 95 patients treated with radiation therapy and <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> [<a href="#rid85">85</a>]. At a median follow-up of 19 months, patients with methylated <em>MGMT</em> had a longer time to initial relapse and were more likely to relapse outside the radiation treatment field (8 of 17 versus 9 of 60 with an unmethylated primary tumor).</p><p>Of note, a number of assays are in clinical use to measure <em>MGMT </em>promoter methylation, and there is no consensus on the optimal method [<a href="#rid86">86-88</a>]. Reliability, availability, and cost vary among methods, and there is a need for better quality control and validation. The proportion of patients with glioblastoma classified as having a methylated <em>MGMT</em> promoter is considered in the range of 40 to 50 percent, although a broader range (30 to 60 percent) may be seen depending on the assay used and study cohort [<a href="#rid89">89-91</a>].</p><p class="headingAnchor" id="H1038085842"><span class="h2">Other molecular factors</span><span class="headingEndMark"> — </span>Mutations in the promoter of the telomerase reverse transcriptase (<em>TERT</em>) gene have been described in 55 to 80 percent of primary glioblastomas and are associated with worse survival, independent of other clinical and molecular factors [<a href="#rid92">92-94</a>]. As of the 2021 World Health Organization (WHO) Classification of Central Nervous System Tumors, the presence of a <em>TERT</em> promoter mutation in an IDH-wildtype astrocytoma establishes a diagnosis of glioblastoma, even in the absence of high-grade histologic features [<a href="#rid1">1</a>]. The same is true for two other molecular features: epidermal growth factor receptor (EGFR) amplification and concurrent gain of chromosome 7/loss of chromosome 10. (See  <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on 'EGFR, TERT, +7/-10 genotype'</a>.)</p><p>Additional molecular alterations in high-grade gliomas are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5223.html" rel="external">"Molecular pathogenesis of diffuse gliomas"</a>.)</p><p class="headingAnchor" id="H267982117"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/130511.html" rel="external">"Society guideline links: Primary brain tumors"</a>.)</p><p class="headingAnchor" id="H33271875"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/82941.html" rel="external">"Patient education: Glioblastoma (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/855.html" rel="external">"Patient education: High-grade glioma in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Note on terminology</strong> – As of 2021, tumors previously called glioblastoma are now divided into two separate diagnoses based primarily on isocitrate dehydrogenase (IDH) mutation status  (<a class="graphic graphic_algorithm graphicRef134946" href="/z/d/graphic/134946.html" rel="external">algorithm 1</a>): glioblastoma, IDH-wildtype, grade 4; and astrocytoma, IDH-mutant, grade 4. For the purposes of this topic, glioblastoma refers to IDH-wildtype glioblastoma unless stated otherwise. Treatment of IDH-mutant astrocytomas is reviewed separately. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/z/d/html/5198.html" rel="external">"Treatment and prognosis of IDH-mutant astrocytomas in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical resection</strong> – Maximal surgical resection consistent with preservation of neurologic function is the initial step in management. Surgical management of high-grade gliomas is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5228.html" rel="external">"Clinical presentation, diagnosis, and initial surgical management of high-grade gliomas"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance of molecular testing</strong> – Selection of appropriate postoperative therapy for patients with glioblastoma and other infiltrative gliomas depends on adequate molecular characterization  (<a class="graphic graphic_table graphicRef115919" href="/z/d/graphic/115919.html" rel="external">table 1</a>). Tumor specimens should be tested for IDH mutations and O6-methylguanine-DNA methyltransferase (<em>MGMT</em>) promoter methylation. (See <a class="local">'Selection of systemic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selection of systemic therapy</strong> – Radiation and <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> are the backbone of initial therapy for newly diagnosed glioblastoma in patients with an adequate functional status. The quality of supporting evidence and alternative treatment options vary based on patient age and <em>MGMT</em> methylation status:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>MGMT</em></strong><strong>-methylated glioblastoma, ≤70 years</strong> – We recommend postoperative radiation therapy with concurrent and adjuvant <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). A dual regimen of temozolomide and <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">lomustine</a> in combination with radiation therapy is an alternative option in younger, fit patients, although data supporting improved efficacy are inconclusive and toxicity may be higher. (See <a class="local">'MGMT-methylated tumors, age ≤70 years'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>MGMT</em></strong><strong>-unmethylated glioblastoma, ≤70 years</strong> – We suggest postoperative radiation therapy with concurrent and adjuvant <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Patients with <em>MGMT</em>-unmethylated tumors have worse overall survival and derive less benefit from temozolomide compared with patients with <em>MGMT</em>-methylated tumors, but better alternatives are lacking. Participation in clinical trials is encouraged. (See <a class="local">'MGMT-unmethylated tumors, age ≤70 years'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unknown </strong><strong><em>MGMT</em></strong><strong> methylation status, ≤70 years</strong> – Radiation plus <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> remains the standard of care based on the clinically meaningful improvement in survival expected from temozolomide for the 30 to 40 percent of patients predicted to have an <em>MGMT</em>-methylated tumor, the lack of better alternatives for <em>MGMT</em>-unmethylated tumors, and the relative safety and tolerability of temozolomide. (See <a class="local">'MGMT status unknown'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Age &gt;70 years or low functional status</strong> – Treatment recommendations for older adults  (<a class="graphic graphic_algorithm graphicRef93333" href="/z/d/graphic/93333.html" rel="external">algorithm 2</a>) and those with poor functional status are presented separately. (See  <a class="medical medical_review" href="/z/d/html/15246.html" rel="external">"Management of glioblastoma in older adults", section on 'Summary and recommendations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration of systemic therapy</strong> – <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">Temozolomide</a> is taken on an empty stomach, at least two hours after the last meal, with antiemetic pretreatment. Patients require regular monitoring of complete blood counts and liver function tests. (See <a class="local">'Administration of systemic therapy'</a> above.)</p><p></p><p class="bulletIndent1">For patients with additional risk factors for opportunistic infection (eg, use of glucocorticoids, lymphopenia), we suggest antimicrobial prophylaxis for pneumocystis pneumonia during radiation with concurrent <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In other patients, the risks of prophylaxis may outweigh the benefits, given the low risk of pneumocystis. (See <a class="local">'Pneumocystis prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of systemic therapy</strong> – For patients treated with standard concurrent and adjuvant <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>, we suggest treating with six cycles of adjuvant monthly temozolomide rather than a more prolonged course (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Treatment duration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive device therapy</strong> – In addition to radiation and <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>, we discuss the option of low-intensity alternating electric field therapy (TTFields), which improved survival in a large randomized trial. Use of the device is encouraged in interested patients, although the requirement to carry a device and maintain a shaved scalp for the duration of treatment presents a potential burden that is not acceptable to all patients. (See <a class="local">'Alternating electric fields'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>– The median overall survival of patients with glioblastoma is approximately 10 to 12 months in population-based studies and approximately 15 to 18 months in clinical trials of standard therapy. The most prognostic factors are age, performance status, and <em>MGMT</em> promoter methylation status. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Central Nervous System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, 2021.</li><li><a class="nounderline abstract_t">Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987.</a></li><li><a class="nounderline abstract_t">Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459.</a></li><li><a class="nounderline abstract_t">Taphoorn MJ, Stupp R, Coens C, et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 2005; 6:937.</a></li><li><a class="nounderline abstract_t">Athanassiou H, Synodinou M, Maragoudakis E, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005; 23:2372.</a></li><li><a class="nounderline abstract_t">Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997.</a></li><li><a class="nounderline abstract_t">Herrlinger U, Tzaridis T, Mack F, et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 2019; 393:678.</a></li><li><a class="nounderline abstract_t">Herrlinger U, Schäfer N, Steinbach JP, et al. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol 2016; 34:1611.</a></li><li><a class="nounderline abstract_t">Omuro A, Brandes AA, Carpentier AF, et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro Oncol 2023; 25:123.</a></li><li><a class="nounderline abstract_t">Redjal N, Nahed BV, Dietrich J, et al. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of chemotherapeutic management and antiangiogenic treatment of newly diagnosed glioblastoma in adults. J Neurooncol 2020; 150:165.</a></li><li><a class="nounderline abstract_t">Khasraw M, Ameratunga MS, Grant R, et al. Antiangiogenic therapy for high-grade glioma. Cochrane Database Syst Rev 2014; :CD008218.</a></li><li><a class="nounderline abstract_t">Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011; 29:142.</a></li><li><a class="nounderline abstract_t">Vredenburgh JJ, Desjardins A, Reardon DA, et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 2011; 17:4119.</a></li><li><a class="nounderline abstract_t">Omuro A, Beal K, Gutin P, et al. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clin Cancer Res 2014; 20:5023.</a></li><li><a class="nounderline abstract_t">Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370:709.</a></li><li><a class="nounderline abstract_t">Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370:699.</a></li><li><a class="nounderline abstract_t">Taphoorn MJ, Henriksson R, Bottomley A, et al. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. J Clin Oncol 2015; 33:2166.</a></li><li><a class="nounderline abstract_t">Wefel JS, Armstrong TS, Pugh SL, et al. Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825). Neuro Oncol 2021; 23:1125.</a></li><li><a class="nounderline abstract_t">Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013; 31:4085.</a></li><li><a class="nounderline abstract_t">Armstrong TS, Wefel JS, Wang M, et al. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol 2013; 31:4076.</a></li><li><a class="nounderline abstract_t">Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 2010; 28:4601.</a></li><li><a class="nounderline abstract_t">Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20:1375.</a></li><li><a class="nounderline abstract_t">Climans SA, Mason WP, Grunfeld E, Chan K. Clinical features of glioma patients who develop pneumocystis pneumonia with temozolomide chemoradiotherapy. J Neurooncol 2022; 159:665.</a></li><li><a class="nounderline abstract_t">Climans SA, Grunfeld E, Mason WP, Chan KKW. Effectiveness and safety of pneumocystis pneumonia prophylaxis for patients receiving temozolomide chemoradiotherapy. Neuro Oncol 2022; 24:1738.</a></li><li class="breakAll">LABEL: TEMOZOLOMIDE capsule. DailyMed. US National Library of Medicine. National Institutes of Health. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d599ccf-8e63-4ff1-aa52-4809744ea97a (Accessed on January 04, 2023).</li><li class="breakAll">National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 2.2014. http://www.nccn.org (Accessed on November 06, 2014).</li><li class="breakAll">Temodar (temozolomide) for injection, prescribing information. http://www.merck.com/product/usa/pi_circulars/t/temodar_capsules/temodar_pi.pdf (Accessed on February 11, 2013).</li><li><a class="nounderline abstract_t">Gerber DE, Grossman SA, Zeltzman M, et al. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 2007; 9:47.</a></li><li><a class="nounderline abstract_t">Grossman SA, Ye X, Lesser G, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 2011; 17:5473.</a></li><li><a class="nounderline abstract_t">Mohan R, Liu AY, Brown PD, et al. Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. Neuro Oncol 2021; 23:284.</a></li><li><a class="nounderline abstract_t">Zeiner PS, Filipski K, Filmann N, et al. Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma. Neurology 2022; 98:e2073.</a></li><li><a class="nounderline abstract_t">Huang J, DeWees TA, Badiyan SN, et al. Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma. Int J Radiat Oncol Biol Phys 2015; 92:1000.</a></li><li><a class="nounderline abstract_t">Le Rhun E, Devos P, Houillier C, et al. Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial. Neurology 2019; 93:e1799.</a></li><li><a class="nounderline abstract_t">Dixit S, Baker L, Walmsley V, Hingorani M. Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review. Anticancer Drugs 2012; 23:1099.</a></li><li><a class="nounderline abstract_t">Neyns B, Cordera S, Joosens E, Pouratian N. Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide. J Clin Oncol 2008; 26:4518.</a></li><li><a class="nounderline abstract_t">Villano JL, Collins CA, Manasanch EE, et al. Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol 2006; 7:436.</a></li><li><a class="nounderline abstract_t">Park AK, Waheed A, Forst DA, Al-Samkari H. Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies. Neuro Oncol 2022; 24:964.</a></li><li><a class="nounderline abstract_t">Singhal N, Selva-Nayagam S, Brown MP. Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature. J Neurooncol 2007; 85:229.</a></li><li><a class="nounderline abstract_t">Jalali R, Singh P, Menon H, Gujral S. Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide. J Neurooncol 2007; 85:105.</a></li><li><a class="nounderline abstract_t">Morris EB, Kasow K, Reiss U, et al. Bone marrow transplantation for severe aplastic anemia secondary to temozolomide. J Neurooncol 2009; 91:237.</a></li><li><a class="nounderline abstract_t">Nagane M, Nozue K, Shimizu S, et al. Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status. J Neurooncol 2009; 92:227.</a></li><li><a class="nounderline abstract_t">George BJ, Eichinger JB, Richard TJ. A rare case of aplastic anemia caused by temozolomide. South Med J 2009; 102:974.</a></li><li><a class="nounderline abstract_t">Kopecký J, Priester P, Slovácek L, et al. Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide. Strahlenther Onkol 2010; 186:452.</a></li><li><a class="nounderline abstract_t">Oh J, Kutas GJ, Davey P, et al. Aplastic anemia with concurrent temozolomide treatment in a patient with glioblastoma multiforme. Curr Oncol 2010; 17:124.</a></li><li><a class="nounderline abstract_t">Chamberlain MC, Raizer J. Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia. J Neurooncol 2009; 93:229.</a></li><li><a class="nounderline abstract_t">Su YW, Chang MC, Chiang MF, Hsieh RK. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neurooncol 2005; 71:315.</a></li><li><a class="nounderline abstract_t">Noronha V, Berliner N, Ballen KK, et al. Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro Oncol 2006; 8:280.</a></li><li><a class="nounderline abstract_t">Dufour C, Da Costa L, Auger N, et al. Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report. J Pediatr Hematol Oncol 2008; 30:857.</a></li><li><a class="nounderline abstract_t">Kushner BH, Laquaglia MP, Kramer K, et al. Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide. Pediatr Blood Cancer 2008; 51:552.</a></li><li><a class="nounderline abstract_t">Kim SJ, Park TS, Lee ST, et al. Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme. Ann Clin Lab Sci 2009; 39:392.</a></li><li><a class="nounderline abstract_t">Momota H, Narita Y, Miyakita Y, Shibui S. Secondary hematological malignancies associated with temozolomide in patients with glioma. Neuro Oncol 2013; 15:1445.</a></li><li><a class="nounderline abstract_t">Karremann M, Krämer N, Hoffmann M, et al. Haematological malignancies following temozolomide treatment for paediatric high-grade glioma. Eur J Cancer 2017; 81:1.</a></li><li><a class="nounderline abstract_t">Goldbecker A, Tryc AB, Raab P, et al. Hepatic encephalopathy after treatment with temozolomide. J Neurooncol 2011; 103:163.</a></li><li><a class="nounderline abstract_t">Dixit S, Hingorani M, Afzal P, Campbell AP. Temozolomide induced liver injury. Acta Neurol Belg 2011; 111:249.</a></li><li><a class="nounderline abstract_t">Sarganas G, Orzechowski HD, Klimpel A, et al. Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. Neuro Oncol 2012; 14:541.</a></li><li class="breakAll">http://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=temozolomide&amp;x=0&amp;y=0 (Accessed on June 16, 2014).</li><li><a class="nounderline abstract_t">Jen JF, Cutler DL, Pai SM, et al. Population pharmacokinetics of temozolomide in cancer patients. Pharm Res 2000; 17:1284.</a></li><li class="breakAll">Temodar (temozolomide capsules and temozolomide injection). US FDA approved product information; Whitehouse Station, NJ: Merck &amp; Co, Inc; November 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021029s033lbl.pdf (Accessed on November 12, 2020).</li><li><a class="nounderline abstract_t">Balana C, Vaz MA, Manuel Sepúlveda J, et al. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). Neuro Oncol 2020; 22:1851.</a></li><li><a class="nounderline abstract_t">Gramatzki D, Kickingereder P, Hentschel B, et al. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Neurology 2017; 88:1422.</a></li><li><a class="nounderline abstract_t">Blumenthal DT, Gorlia T, Gilbert MR, et al. Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro Oncol 2017; 19:1119.</a></li><li><a class="nounderline abstract_t">Weller J, Schäfer N, Schaub C, et al. Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial. J Neurooncol 2023; 161:147.</a></li><li><a class="nounderline abstract_t">Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 2012; 48:2192.</a></li><li><a class="nounderline abstract_t">Stupp R, Taillibert S, Kanner AA, et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA 2015; 314:2535.</a></li><li><a class="nounderline abstract_t">Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA 2017; 318:2306.</a></li><li><a class="nounderline abstract_t">Zhu JJ, Demireva P, Kanner AA, et al. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. J Neurooncol 2017; 135:545.</a></li><li><a class="nounderline abstract_t">Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 2018; 4:495.</a></li><li><a class="nounderline abstract_t">Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res 2004; 64:3288.</a></li><li><a class="nounderline abstract_t">Kirson ED, Dbalý V, Tovarys F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A 2007; 104:10152.</a></li><li class="breakAll">NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on February 11, 2022).</li><li><a class="nounderline abstract_t">Ostrom QT, Gittleman H, Xu J, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013. Neuro Oncol 2016; 18:v1.</a></li><li><a class="nounderline abstract_t">Korja M, Raj R, Seppä K, et al. Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland. Neuro Oncol 2019; 21:370.</a></li><li><a class="nounderline abstract_t">Ostrom QT, Shoaf ML, Cioffi G, et al. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. Neuro Oncol 2023; 25:799.</a></li><li><a class="nounderline abstract_t">Chien LN, Gittleman H, Ostrom QT, et al. Comparative Brain and Central Nervous System Tumor Incidence and Survival between the United States and Taiwan Based on Population-Based Registry. Front Public Health 2016; 4:151.</a></li><li><a class="nounderline abstract_t">Gramatzki D, Dehler S, Rushing EJ, et al. Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer 2016; 122:2206.</a></li><li><a class="nounderline abstract_t">Gittleman H, Lim D, Kattan MW, et al. An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro Oncol 2017; 19:669.</a></li><li><a class="nounderline abstract_t">Molitoris JK, Rao YJ, Patel RA, et al. Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation. J Neurooncol 2017; 134:331.</a></li><li><a class="nounderline abstract_t">Li J, Wang M, Won M, et al. Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys 2011; 81:623.</a></li><li><a class="nounderline abstract_t">Scott JG, Bauchet L, Fraum TJ, et al. Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer 2012; 118:5595.</a></li><li><a class="nounderline abstract_t">Zhao H, Wang S, Song C, et al. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis. World J Surg Oncol 2016; 14:261.</a></li><li><a class="nounderline abstract_t">Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008; 26:4189.</a></li><li><a class="nounderline abstract_t">Brandes AA, Franceschi E, Tosoni A, et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 2009; 115:3512.</a></li><li><a class="nounderline abstract_t">Gerstner ER, Yip S, Wang DL, et al. Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology 2009; 73:1509.</a></li><li><a class="nounderline abstract_t">Reifenberger G, Hentschel B, Felsberg J, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 2012; 131:1342.</a></li><li><a class="nounderline abstract_t">Brandes AA, Tosoni A, Franceschi E, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol 2009; 27:1275.</a></li><li><a class="nounderline abstract_t">Mansouri A, Hachem LD, Mansouri S, et al. MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro Oncol 2019; 21:167.</a></li><li><a class="nounderline abstract_t">McAleenan A, Kelly C, Spiga F, et al. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. Cochrane Database Syst Rev 2021; 3:CD013316.</a></li><li><a class="nounderline abstract_t">Brandner S, McAleenan A, Kelly C, et al. MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. Neuro Oncol 2021; 23:1457.</a></li><li><a class="nounderline abstract_t">Hegi ME, Genbrugge E, Gorlia T, et al. MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. Clin Cancer Res 2019; 25:1809.</a></li><li><a class="nounderline abstract_t">Yuan G, Niu L, Zhang Y, et al. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. J Neurooncol 2017; 133:193.</a></li><li><a class="nounderline abstract_t">Wang L, Li Z, Liu C, et al. Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas. Pathol Res Pract 2017; 213:1489.</a></li><li><a class="nounderline abstract_t">Simon M, Hosen I, Gousias K, et al. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol 2015; 17:45.</a></li><li><a class="nounderline abstract_t">Nonoguchi N, Ohta T, Oh JE, et al. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 2013; 126:931.</a></li><li><a class="nounderline abstract_t">Labussière M, Boisselier B, Mokhtari K, et al. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology 2014; 83:1200.</a></li></ol></div><div id="topicVersionRevision">Topic 5207 Version 82.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Central Nervous System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15758009" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19269895" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16321761" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Health-related quality of life in patients with glioblastoma: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800329" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15758010" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : MGMT gene silencing and benefit from temozolomide in glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30782343" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26976423" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35419607" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33215343" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of chemotherapeutic management and antiangiogenic treatment of newly diagnosed glioblastoma in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25242542" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Antiangiogenic therapy for high-grade glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21135282" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21531816" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25107913" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24552318" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24552317" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A randomized trial of bevacizumab for newly diagnosed glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26014298" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33515019" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24101040" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24101048" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855843" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11870182" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35932358" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical features of glioma patients who develop pneumocystis pneumonia with temozolomide chemoradiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35312784" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effectiveness and safety of pneumocystis pneumonia prophylaxis for patients receiving temozolomide chemoradiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35312784" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effectiveness and safety of pneumocystis pneumonia prophylaxis for patients receiving temozolomide chemoradiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35312784" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effectiveness and safety of pneumocystis pneumonia prophylaxis for patients receiving temozolomide chemoradiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35312784" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effectiveness and safety of pneumocystis pneumonia prophylaxis for patients receiving temozolomide chemoradiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17108062" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21737504" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32750703" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35351796" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26025775" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31586022" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22850321" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18802168" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16648049" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34647594" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17530175" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17505778" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18818880" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Bone marrow transplantation for severe aplastic anemia secondary to temozolomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19037596" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19668033" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A rare case of aplastic anemia caused by temozolomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20803286" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20697524" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Aplastic anemia with concurrent temozolomide treatment in a patient with glioblastoma multiforme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19099199" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15735923" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16728498" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18989164" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18570300" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19880768" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23519741" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Secondary hematological malignancies associated with temozolomide in patients with glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28586748" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Haematological malignancies following temozolomide treatment for paediatric high-grade glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20730617" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Hepatic encephalopathy after treatment with temozolomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22141295" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Temozolomide induced liver injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22394496" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22394496" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11145236" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Population pharmacokinetics of temozolomide in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11145236" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Population pharmacokinetics of temozolomide in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32328662" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28298550" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28371907" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36609807" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22608262" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26670971" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29260225" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28849310" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29392280" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15126372" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Disruption of cancer cell replication by alternating electric fields.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17551011" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17551011" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28475809" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30312433" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35994777" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27493936" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Comparative Brain and Central Nervous System Tumor Incidence and Survival between the United States and Taiwan Based on Population-Based Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27088883" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28453749" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28643151" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20888136" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22517216" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27733166" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757334" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19514084" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19884580" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22139906" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19188675" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30189035" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33710615" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34467991" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30514777" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28516344" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29103769" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25140036" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23955565" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : TERT promoter mutations in primary and secondary glioblastomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25150284" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
